Emicizumab: A Promising Option for Hemostatic Control in Acquired Hemophilia A

Acquired hemophilia A (AHA) is caused by development of autoantibodies or inhibitors against coagulation factor VIII, resulting in life-threatening bleeding diathesis. Hemostatic therapy with factor VIII bypassing agents is critical until inhibitors are eradicated; however, breakthrough bleeding and thromboembolic complications continue to be major problems. Immunosuppressive therapy (IST) remains the primary therapeutic option for inhibitor eradication. Emicizumab is a bispecific monoclonal antibody that mimics the function of activated factor VIII and achieves hemostasis even in the presence of inhibitors; it is approved for the treatment of congenital hemophilia A with and without inhibitors.

In an industry-funded, open-label, single-arm,…